Pfizer Corporation Hong Kong Limited 美國輝瑞科研製藥

UNDER

Indication^1,2

Treatment of essential hypertension.

Clinical Evidence

Olmesartan maintained systolic blood pressure (SBP) and diastolic blood pressure (DBP) at lower levels over a 24-hour period than losartan, valsartan and irbesartan³

Unsurpassed efficacy even in the early morning BP surge³

Significantly reduced the following vascular microinflammation markers in hypertensive patients as early as week 6⁴

Plaque volume decreased significantly with olmesartan compared with atenolol⁵

Wall-to-lumen ratio reduced significantly with olmesartan (14.9% to 11.1%, p<0.01); no significant change observed with atenolol⁶

Safety Profile^1,2

CI:	Olmetec Hypersensitivity to olmesartan medoxomil or any of the other excipients of Olmetec. Biliary obstruction. 2^nd and 3^rd trimesters of pregnancy, lactation. Olmetec Plus Pregnancy. Hypersensitivity to any component of Olmetec Plus. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

SP:	Olmetec Intravascular volume depletion. Bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. Renal and hepatic impairment. Hyperkalaemia especially in renal impairment and/or heart failure. Aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy. Primary aldosteronism, excessive decrease in blood pressure in patients with ischaemic heart disease or ischaemic cerebrovascular disease, combination of lithium, other conditions with stimulation of the renin-angiotensin-aldosterone system. Olmetec Plus Patients with volume or salt depletion, history of allergy or bronchial asthma. Renal/hepatic impairment. Children, elderly. Lactation.

AR:	Dizziness, bronchitis, cough, pharyngitis, rhinitis, abdominal pain, diarrhoea, dyspepsia, gastroenteritis, nausea, back, joint, skeletal and chest pain, fatigue, influenza-like symptoms, peripheral oedema, haematuria, urinary tract infection, increased creatine phosphokinase, hypertriglyceridaemia, hyperuricaemia, liver enzyme elevations.

DI:	Olmetec Lithium, other antihypertensives, antacids, nonsteroidal anti-inflammatory drugs (NSAIDs). Concomitant use of potassium (K)-sparing diuretics, K supplements, salt substitutes containing K. Olmetec Plus Alcohol, barbiturates, narcotics, antidiabetic drugs, other antihypertensives, cholestyramine and colestipol resins, corticosteroids, adrenocorticotropic hormone (ACTH), pressor amines, eg, norepinephrine, nondepolarizing skeletal muscle relaxants, eg, tubocurarine, lithium, NSAIDs.

Dosages^1,2

Olmetec 20 mg once daily. May be increased to max 40 mg daily or add hydrochlorothiazide therapy. Olmetec Plus 1 tab once daily.

Strengths^1,2

Olmetec 10 mg, 20 mg, 40 mg.
Olmetec Plus 20 mg/12.5 mg.

Packing^1,2

Olmetec Film-coated tab 10 mg x 30's. 20 mg x 30's. 40 mg x 30's.
Olmetec Plus Tab 20 mg/12.5 mg x 30's.

References

1. MIMS Annual Hong Kong. 2007/2008 edition.
2. Olmetc Plus™ full prescribing information. Pfizer; June 2006.
3. Smith DH, et al. Am J Cardiovasc Drugs 2005;5:41-50.
4. Fliser D, et al. Circulation 2004;110:1103-1107.
5. Stumpe KO, et al. Ther Adv Cardiovasc Dis 2007;1:97-106.
6. Smith RD, et al. J Am Soc Hypertens 2008;2:165-172.

Please review the full product information or package insert before prescribing.